



# Developing An International Horizon Scanning Approach



Carlie LaLone, Ph.D.  
Research Bioinformaticist  
U.S. Environmental Protection Agency



# SETAC Pellston Workshop Series





- Named for the UM Biological Station in Pellston, MI where the 1<sup>st</sup> Pellston Workshop took place in 1977
- **High visibility topics/challenges in environmental sciences/regulation, often international in scope**
- Attendance by invitation only; typically 40-50 experts representing the tripartite nature of SETAC
- “Sequestered” setting with long hours discussing/writing
- Usually 4-5 topic-oriented workgroups, each producing a chapter/journal article
- **Selection of topics typically made by Steering Committee, but this can limit scope for broad issues**

## Evolution of the Adverse Outcome Pathway Conceptual Framework

- 2007 — National Research Council Report “Toxicity Testing in the 21st Century: a Vision and a Strategy”
- 2009 — Pellston Workshop “A Vision and Strategy for Predictive Ecotoxicology in the 21st Century”
- 2010 — Initial Publication describing the AOP Framework by Ankley et al. (Environ. Toxicol. Chem. 29:730-741).
- 2012 — The Organisation of Economic Cooperation and Development launches international AOP development programme.
- 2013 — The Organisation of Economic Cooperation and Development Publication “Guidance Document on Developing and Assessing AOPs”
- 2014 — Release of the AOP Wiki  
— Soma Lombardo Workshop: “Advancing AOPs For Integrated Toxicology and Regulatory Applications”
- 2015 — Joint Research Centre, Ispra Workshop: “AOP-informed predictive modeling approaches for regulatory toxicology”

An Adverse Outcome Pathway (AOP) is a conceptual framework that portrays existing knowledge concerning the linkage between a direct molecular initiating event and an adverse outcome, at a level of biological organization relevant to risk assessment.

(Ankley et al. 2010. Environ. Toxicol. Chem., 29(3): 730-741.)



**Users' handbook**  
supplement to OECD guidance document for developing and assessing AOPs.

Relatively small community guiding the direction of the AOP framework

Horizon Scanning!!



## Horizon Scanning

- Horizon scanning—a **method of systematically searching for and identifying emerging trends, opportunities, and limitations that might impact the future directions of a defined subject**
- Provides an opportunity to expand **input from few contributors to many**
- At a finer scale, research identification and prioritization exercises have been used to **identify important and actionable research questions** that can help align scientific effort with policy priorities

### Example of Success:

Boxall, A.B., Rudd, M.A., Brooks, B.W., Caldwell, D.J., Choi, K., Hickmann, S., Innes, E., Ostapyk, K., Staveley, J.P., Verslycke, T. and Ankley, G.T., 2012. Pharmaceuticals and personal care products in the environment: what are the big questions?. *Environmental health perspectives*, 120(9), pp.1221-1229.

Cited 997 times!!!!

# Setting the Stage for the Pellston Workshop

## Phase 1

## Phase 2

## Phase 3





# Adverse Outcome Pathways

## What Outstanding Challenges Must Be Addressed?

The Society of Environmental Toxicology and Chemistry ([SETAC](#)) is initiating Horizon Scanning effort chaired by Drs. Carlie LaLone and Markus Hecker to advance the science and application of the Adverse Outcome Pathway framework. For further information, [click here](#).

This initiative was proposed and approved as a first step in developing themes for an upcoming SETAC Pellston Workshop: **Advancing the Adverse Outcome Pathway Concept – An International Horizon Scanning Approach**.

In this survey we ask you to **please propose questions that consider key outstanding challenges or limitations that must be addressed in order to realize the full potential of the adverse outcome pathway framework in research and regulatory decision making**. Please consider developing questions pertinent to your field, sector, and/or geographic location.

We recommend that you submit your questions using a **computer keyboard or tablet**, rather than smart phone.

Click below to proceed and submit your questions.



**Open March 7<sup>th</sup>-June 30<sup>th</sup> 2016**

Next

In support of an upcoming SETAC Pellston Workshop, "Advancing the Adverse Outcome Pathway Concept – An International Horizon Scanning Approach."

An initiative of the [SETAC World Council](#), U.S. EPA, and University of Saskatchewan. For more information, see the [FAQ](#) or contact [Carlie LaLone](#) or [Markus Hecker](#).

Intro page  
with links  
to key  
information

# Adverse Outcome Pathways

## What Outstanding Challenges Must Be Addressed?

### Who is Submitting Questions?

Are you submitting questions as an individual or an organization?

- ☐ I am submitting questions on **my own behalf**
- ☐ I am submitting questions on behalf of more than one person in **my organization**

<< Next

In support of an upcoming SETAC Pellston Workshop, "Advancing the Adverse Outcome Pathway Concept – An International Horizon Scanning Approach."

An initiative of the [SETAC World Council](#), U.S. EPA, and University of Saskatchewan. For more information, see the [FAQ](#) or contact [Carlie LaLone](#) or [Markus Hecker](#).

411 accessed the website  
147 individual submissions  
11 group submissions

# Adverse Outcome Pathways

What Outstanding Challenges Must Be Addressed?

## Requested Information

Which sector do you work in?

- |   |  |
|---|--|
| <input type="checkbox"/> Academia (faculty)             | <input type="checkbox"/> Industry (consulting)                       |
| <input type="checkbox"/> Academia (staff)               | <input type="checkbox"/> Industry (manufacturing)                    |
| <input type="checkbox"/> Academia (student)             | <input type="checkbox"/> Industry (other)                            |
| <input type="checkbox"/> Government (research)          | <input type="checkbox"/> Non-governmental organization               |
| <input type="checkbox"/> Government (management/policy) | <input type="checkbox"/> Other (please specify) <input type="text"/> |

In which country do you live?

- |   |   |  |
|---|---|--|
| <input type="radio"/> Afghanistan                 | <input type="radio"/> Gambia, The                       | <input type="radio"/> Niue                     |
| <input type="radio"/> Akrotiri                    | <input type="radio"/> Gaza Strip                        | <input type="radio"/> Norfolk Island           |
| <input type="radio"/> Albania                     | <input type="radio"/> Georgia                           | <input type="radio"/> Northern Mariana Islands |
| <input type="radio"/> Algeria                     | <input type="radio"/> Germany                           | <input type="radio"/> Norway                   |
| <input type="radio"/> American Samoa              | <input type="radio"/> Ghana                             | <input type="radio"/> Oman                     |
| <input type="radio"/> Andorra                     | <input type="radio"/> Gibraltar                         | <input type="radio"/> Pakistan                 |
| <input type="radio"/> Angola                      | <input type="radio"/> Glorioso Islands                  | <input type="radio"/> Palau                    |
| <input type="radio"/> Anguilla                    | <input type="radio"/> Greece                            | <input type="radio"/> Panama                   |
| <input type="radio"/> Antarctica                  | <input type="radio"/> Greenland                         | <input type="radio"/> Papua New Guinea         |
| <input type="radio"/> Antigua and Barbuda         | <input type="radio"/> Grenada                           | <input type="radio"/> Paracel Islands          |
| <input type="radio"/> Argentina                   | <input type="radio"/> Guadeloupe                        | <input type="radio"/> Paraguay                 |
| <input type="radio"/> Armenia                     | <input type="radio"/> Guam                              | <input type="radio"/> Peru                     |
| <input type="radio"/> Aruba                       | <input type="radio"/> Guatemala                         | <input type="radio"/> Philippines              |
| <input type="radio"/> Ashmore and Cartier Islands | <input type="radio"/> Guernsey                          | <input type="radio"/> Pitcairn Islands         |
| <input type="radio"/> Australia                   | <input type="radio"/> Guinea                            | <input type="radio"/> Poland                   |
| <input type="radio"/> Austria                     | <input type="radio"/> Guinea-Bissau                     | <input type="radio"/> Portugal                 |
| <input type="radio"/> Azerbaijan                  | <input type="radio"/> Guyana                            | <input type="radio"/> Puerto Rico              |
| <input type="radio"/> Bahamas, The                | <input type="radio"/> Haiti                             | <input type="radio"/> Qatar                    |
| <input type="radio"/> Bahrain                     | <input type="radio"/> Heard Island and McDonald Islands | <input type="radio"/> Reunion                  |
| <input type="radio"/> Bangladesh                  | <input type="radio"/> Holy See (Vatican City)           | <input type="radio"/> Romania                  |
|   |   | <input type="radio"/> Russia                   |

Put most valuable information we wanted to collect prior to the main question collection page



# Adverse Outcome Pathways

## What Outstanding Challenges Must Be Addressed?

### Submit a Question

Please propose questions that consider **key outstanding challenges or limitations that must be addressed in order to realize the full potential of the adverse outcome pathway framework** in research and regulatory decision making.

Consider developing questions pertinent to your field, sector, and/or geographic location.

#### Question Criteria:

- Address important knowledge gaps
- Factual answer that does not depend on value judgement
- Cover a spatial and temporal scale that realistically can be addressed by expert groups
- Cannot be answered by "yes," "no," or "it all depends" answers

Please limit the question itself to 300 characters.

If you would like to provide rationale for your question or references (to 3000 characters) please use the space below.

You can submit up to a total of 20 candidate questions. Would you like to submit another question?

☐ Yes ☐ No



In support of an upcoming SETAC Pellston Workshop, "Advancing the Adverse Outcome Pathway Concept – An International Horizon Scanning Approach."

An Initiative of the [SETAC World Council](#), U.S. EPA, and University of Saskatchewan. For more information, see the [FAQ](#) or contact [Carlie LaLone](#) or [Markus Hecker](#).

340 questions

This was helpful and many did provide rationale



# Adverse Outcome Pathways

## What Outstanding Challenges Must Be Addressed?

### Requested Information

How long have you worked in fields related to toxicology?

- ☐ 5 years or less    ☐ 11 to 20 years    ☐ More than 30 years  
☐ 6 to 10 years    ☐ 21 to 30 years    ☐ Not applicable

Please select your area of primary expertise.

- |  |   |
|--|---|
| <input type="checkbox"/> Aquatic toxicology                    | <input type="checkbox"/> Ecological risk assessment                                 |
| <input type="checkbox"/> Aquatic ecology                       | <input type="checkbox"/> Human health risk assessment                               |
| <input type="checkbox"/> Terrestrial or wildlife toxicology    | <input type="checkbox"/> Human toxicology   |
| <input type="checkbox"/> Terrestrial or wildlife ecology       | <input type="checkbox"/> Risk management, risk communication, and/or science policy |
| <input type="checkbox"/> Environmental or analytical chemistry | <input type="checkbox"/> Other (please specify) <input type="text"/>                |

How many peer-reviewed journal articles have you published relevant to adverse outcome pathway framework? (does not specifically have to include AOP descriptions, but relevant to this body of work)

- ☐ 0 articles    ☐ 6 to 10 articles    ☐ 51 to 100 articles  
☐ 1 to 2 articles    ☐ 11 to 25 articles    ☐ Over 100 articles  
☐ 3 to 5 articles    ☐ 26 to 50 articles

<<    Next

In support of an upcoming SETAC Pellston Workshop, "Advancing the Adverse Outcome Pathway Concept – An International Horizon Scanning Approach."

An Initiative of the [SETAC World Council](#), U.S. EPA, and University of Saskatchewan. For more information, see the [FAQ](#) or contact [Carlie LaLone](#) or [Markus Hecker](#).

Put least valuable information after the main question collection page in case the participant didn't finish the questionnaire

# Adverse Outcome Pathways

## What Outstanding Challenges Must Be Addressed?

### Requested Information

Are you a member of these societies? (if you are active in others, please provide up to a maximum of 3)

- ☐ Society for Ecotoxicology and Chemistry (SETAC)
- ☐ Society of Toxicology (SOT)
- ☐ American Chemical Society (ACS)
- ☐ Other (please specify)
- ☐ Other (please specify)
- ☐ Other (please specify)

Are you a member of any SETAC advisory groups? Please check all that apply.

- |  |  |
|--|--|
| <input type="checkbox"/> Europe: Dug Organism Toxicity Testing   | <input type="checkbox"/> Global: Endocrine Disruptor Testing and Risk Assessment       |
| <input type="checkbox"/> Europe: Environmental Monitoring Advisory Group on Pesticides                 | <input type="checkbox"/> Global: Exposure Modeling                                     |
| <input type="checkbox"/> Europe: Extreme Stress Events and Ecosystem Recovery                          | <input type="checkbox"/> Global: Global Soils  |
| <input type="checkbox"/> Europe: Mechanistic Effect Models for Ecological Risk Assessment of Chemicals | <input type="checkbox"/> Global: Life Cycle Assessment (LCA) Global Coordinating Group |
| <input type="checkbox"/> Europe: REACH   | <input type="checkbox"/> Global: Metals  |
| <input type="checkbox"/> Global: Animal Alternatives in Environmental Science                          | <input type="checkbox"/> Global: Nanotechnology  |
| <input type="checkbox"/> Global: Aquatic Macrophyte Ecotoxicology                                      | <input type="checkbox"/> Global: Pharmaceuticals                                       |
| <input type="checkbox"/> Global: Bioaccumulation Science   | <input type="checkbox"/> Global: Sediments   |
| <input type="checkbox"/> Global: Ecological Risk Assessment  | <input type="checkbox"/> Global: Sustainability  |
| <input type="checkbox"/> Global: Ecosystem Services  | <input type="checkbox"/> North America: Chemistry                                      |
| <input type="checkbox"/> Global: Ecotoxicology of Amphibians and Reptiles                              | <input type="checkbox"/> North America: Human Health Risk Assessment                   |

<<

Next

In support of an upcoming SETAC Pellston Workshop, "Advancing the Adverse Outcome Pathway Concept – An International Horizon Scanning Approach."

An Initiative of the [SETAC World Council](#), U.S. EPA, and University of Saskatchewan. For more information, see the [FAQ](#) or contact [Carlie LaLone](#) or [Markus Hecker](#).

# Adverse Outcome Pathways

## What Outstanding Challenges Must Be Addressed?

### Follow-Up

If you would like to be acknowledged for the questions you submitted, please provide your name and/or organization below. If you choose not to provide your name, your questions will be anonymous.

First Name:

Last Name:

Organization:



Next

In support of an upcoming SETAC Pellston Workshop, "Advancing the Adverse Outcome Pathway Concept – An International Horizon Scanning Approach."

An Initiative of the [SETAC World Council](#), U.S. EPA, and University of Saskatchewan. For more information, see the [FAQ](#) or contact [Carlie LaLone](#) or [Markus Hecker](#).


97 People provided their name

## Steering Committee Reach out Personally to Network

*Xiaowei Zhang*  
Nanjing University



*Dries Knapen*  
University of Antwerp



*Daniel Villeneuve*  
US EPA



*Maurice Whelan*  
Joint Research Council



*Edward Perkins*  
US Army



*Scott Belanger*  
Procter and Gamble



*Geoff Hodges*  
Unilever



*Michelle Embry*  
HESI



*Sharon Munn*  
Joint Research Council



*Kate Willett*  
The Humane Society of the US



## Workshop Co-chairs



*Carlie LaLone*  
US EPA



*Markus Hecker*  
University of Saskatchewan

## The Team



*Greg Schiefer*  
SETAC



*Nikki Mayo*  
SETAC



*Tamar Schlekot*  
SETAC

## Senior Advisor



*Gerald Ankley*  
US EPA

## Consultant



*Murray Rudd*  
Emory College



Advertise at professional meetings and through SETAC communications

- Globe Article
- Member email list
- SETAC News letter

## WE NEED YOUR QUESTIONS TODAY!

WHAT QUESTIONS DO YOU HAVE ABOUT AOPS?  
WHAT ARE THE CHALLENGES FOR THEIR APPLICATION?

Please take ~5 minutes and submit your thoughts via this SETAC sponsored survey:

<https://AOP.sawtoothsoftware.com/login.html>

Contact Carlie LaLone; [LaLone.Carlie@epa.gov](mailto:LaLone.Carlie@epa.gov) or Markus Hecker; [Markus.hecker@usask.ca](mailto:Markus.hecker@usask.ca) for details

Survey responses will guide an upcoming *SETAC Pellston Workshop* on AOPs

## Join us in: Advancing the Adverse Outcome Pathway Concept – An International Horizon Scanning Approach



The Society for Environmental Toxicology and Chemistry (SETAC) is initiating a Horizon Scanning effort to advance the science and application of the Adverse Outcome Pathway (AOP) framework.

### Objective:

To seek your participation in shaping the direction of the Adverse Outcome Pathway (AOP) Framework and its applications.

This Horizon Scanning approach will allow us to identify and begin to address recognized, on-going, and remaining issues relevant to the application of the AOP framework to chemical risk assessment in the context of both human and ecological health. Through **your participation**, as a member of the global scientific community, we ask that you:

***Propose questions that consider key outstanding challenges or limitations that must be addressed in order to realize the full potential of the adverse outcome pathway framework in research and regulatory decision-making.***

You can **submit your questions** using the following link (open March 7 – June 30, 2016):

<https://AOP.sawtoothsoftware.com/login.html>

**Your questions are essential** for developing themes to be addressed during an up-coming, expert-led, 2017 Pellston workshop. Workshop results will be publically disseminated in the form of publications and international presentations at professional meetings.

### Background:

Regulatory agencies and industry worldwide are confronted with the challenging task of assessing the risks of thousands of chemicals to the environment and human health. Traditional toxicity testing strategies rely on whole animal studies, which, in addition to ethical concerns, are cost and time prohibitive. As a result, the utility of mechanistic-based approaches to support chemical safety evaluations have increasingly been explored. One approach that has gained traction for capturing available knowledge for describing the linkage between mechanistic data and apical toxicity endpoints required for regulatory assessments is the AOP framework (<http://www.oecd.org/env/ehs/testing/adverse-outcome-pathways-molecular-screening-and-toxicogenomics.htm>). A number of workshops and expert meetings held over the past years, however, illustrated the necessity of expert advice for moving the science of AOPs and their applications forward. This Horizon Scanning question solicitation effort is **your opportunity to have your voice heard** in the conversations surrounding the AOP framework and how it may be used, or could be better defined, for regulatory purposes.

**We greatly appreciate your support of this initiative!**

For further information please contact the co-chairs of this workshop, Dr. Carlie LaLone ([laLone.carlie@epa.gov](mailto:laLone.carlie@epa.gov)) and Dr. Markus Hecker ([markus.hecker@usask.ca](mailto:markus.hecker@usask.ca)); Co-Chairs



# Adverse Outcome Pathway (AOP) Horizon Scanning Effort

SETAC is holding a Horizon Scanning effort to advance the science and application of the AOP framework.

Please take ~5 minutes (prior to June 30<sup>th</sup>) and submit your thoughts via this survey:

<https://AOP.sawtoothsoftware.com/login.html>

The survey will prompt you to:

**Propose questions that consider key outstanding challenges or limitations that must be addressed in order to realize the full potential of the adverse outcome pathway framework in research and regulatory decision-making.**



In Promotion of the Horizon Scanning Effort:

Join one of the founders of the AOP Framework, **Dr. Gerald Ankley**, via **webinar** as he describes the evolution of the AOP construct from its origin to present day!!

**Title: “Evolution of the AOP Framework as a Tool Supporting Chemical Risk Assessment In the 21<sup>st</sup> Century”**

When: June 22<sup>nd</sup>, 2016

Time: 9:00 AM U.S. Central Standard Time Zone

Webinar: [https://epawebconferencing.acms.com/med\\_seminar](https://epawebconferencing.acms.com/med_seminar)

Enter as a Guest\*

Conference line: 1-866-299-3188

Conference code: 529 5035





**Join Dr. Gerald Ankley via Webinar**

## Diversity of backgrounds: Participants by location, sector, and area of expertise



**340** valid questions collected



# Horizon Scanning to Expert Ranking/Prioritization Exercise

## Best-Worst Ranking Exercise

### Phase 2: Theme Development

Steering Committee rank and prioritize questions

Developed broad topics for ranking exercise

1. AOP networks
2. qAOP
3. Collaboration and communication of AOPs
4. AOP discovery and development
5. Extrapolation
6. Exposure/toxicokinetics considerations
7. Application of AOPs

**AOP Workshop Candidate Questions**

**Theme E - Exposure**

Considering **only the four questions below** for now, which do you consider of greater and lesser relative importance?

(Ranking comparison 22 of 22)

Relatively <b>least</b> important	Relatively <b>most</b> important	Candidate question submission
<input type="radio"/>	<input checked="" type="radio"/>	How will quantitative information on the relationships between key events in the pathways be extrapolated to in vivo exposures, so that predictions of toxicity can be considered in the context of actual levels of human or environmental exposure?
<input type="radio"/>	<input type="radio"/>	Can AOP inform recovery, or resiliency following exposure?
<input type="radio"/>	<input type="radio"/>	How can we better incorporate exposure and PBPK information (e.g., chemical specific information) into the AOP wiki?
<input checked="" type="radio"/>	<input type="radio"/>	How do dose-response data link to AOPs?

Click the 'Next' button to continue...

← →

0% 100%

Questions about the survey? Please email [Murray Rudd](#) at Emory University for clarifications.

Removed questions that could be readily answered by an expert familiar with the AOP construct

# Best-Worst Ranking Exercise – Steering Committee

## AOP Workshop Candidate Questions



**Theme E - Exposure**

Considering **only the four questions below** for now, which do you consider of greater and lesser relative importance?

(Ranking comparison 22 of 22)

Relatively <b>least</b> important	Relatively <b>most</b> important	Candidate question submission
<input type="radio"/>	<input checked="" type="radio"/>	How will quantitative information on the relationships between key events in the pathways be extrapolated to in vivo exposures, so that predictions of toxicity can be considered in the context of actual levels of human or environmental exposure?
<input type="radio"/>	<input type="radio"/>	Can AOP inform recovery, or resiliency following exposure?
<input type="radio"/>	<input type="radio"/>	How can we better incorporate exposure and PBPK information (e.g., chemical specific information) into the AOP wiki?
<input checked="" type="radio"/>	<input type="radio"/>	How do dose-response data link to AOPs?

Click the 'Next' button to continue...



0%100%

Questions about the survey? Please email [Murray Rudd](#) at Emory University for clarifications.

Challenge to get all Steering committee to participate

# Output from Best-Worst Ranking Exercise

## Questions from Horizon Scanning

Final workshop questions - Theme E

For Each Topic Area

Column for each expert participant

Considering the importance of internal exposure and chemical specific properties to determine toxicity, what strategies or approaches can we put in place to systematically incorporate these factors into the development process of qAOPs?  
How can ADME processes be incorporated into the AOP concept, or in its application to defined species and/or chemicals?  
How can exposure/dose be efficiently incorporated into the AOP framework?  
How will quantitative information on the relationships between key events in the pathways be extrapolated to in vivo exposures, so that predictions of toxicity can be considered in the context of actual levels of human or environmental exposure?

How should we include PD/PK in future AOPs  
Is there a way to discern the exposures needed to trigger the MIE and quantify the magnitude of the resulting AOs?  
How does one make the quantitative/predictive linkage between in vitro MIE dose-response data and in vivo KE dose-responses?  
How can we better incorporate the exposure side of the risk equation into consideration of AOPs?

Hardly in real environments are organisms and/or populations exposed to one or a few substances. Rather the stressor is a complex mixture and a combination of additional factors such as photo-induced activations, low energy mixing, pulsed exposures, so can AOPs account for this and be effective?

How should we include bioavailability models in AOPs for environmental risk assessment

how can we better understand AOP and dose effects response and relation to environmental exposure : different dose results in a different molecular initiating event (MIE) and therefore different biomarkers are affected.  
How do we extrapolate an in vitro effect concentration to an in vivo effect concentration? (An active area of research, but this question is by no means answered)

To what extent (if any) can exposure pathways affect an AOP for a particular compound or compound class?

How are chemical-agnostic AOPs connected with chemical-specific exposure and hazard information to inform risk assessment and characterization?

How to deal with the dose response curve and ensure that the pathway that you are examining represents one that is representative of environmental exposures.

How could species specific differences in AOPs due to different metabolism of chemicals be addressed?

How will AOPs response be correlated to an exposure relationship that is meaningful to human risk assessment?

How do dose-response data link to AOPs?

Carlie LaLone	Column for each expert participant										Top - bottom
2											7
3	9	5	2			7	4			6 0	6
9		4	5	5	6	8	31			6 1	5
1		6	27	2	3		1	3		6 1	5
			8	9	30	4	5	9		5 1	4
8	1			1			8	26		4 1	3
6				8				8		3 0	3
	2		3	4		2		34		4 1	3
4		9	30	30		9	6	2		5 2	3
		34				6	7	1		3 1	2
7						1				2 0	2
	8					9				2 0	2
						7		3		2 0	2
35		3				2			6	3 1	2
							1			1 0	1
	3	1	32							2 1	1
28	7			6	35					2 2	0
	5					33	35			1 2	-1

Highest Ranked


Lowest Ranked



# Initial Question Categorization

- Developed broad topics to bin questions for ranking exercise

1. AOP networks
2. qAOP
3. Collaboration and communication of AOPs
4. AOP discovery and development
5. Extrapolation
6. Exposure/toxicokinetics considerations
7. Application of AOPs



- Removed questions that could be readily answered by an expert familiar with the AOP construct – Included and answered in overview manuscript: **Advancing the Adverse Outcome Pathway Framework – An international Horizon Scanning Approach** (2017) Environmental Toxicology and Chemistry
  - Example: What is the origin of the AOP framework? Has the concept been peer reviewed? Is there potential profit for the concept proposers? How does the concept differ from established, peer-reviewed concepts of adverse effects? Does the concept include possibilities of beneficial outcomes?



In This Issue:

# ET&C FOCUS

---

Focus articles are part of a regular series intended to sharpen understanding of current and emerging topics of interest to the scientific community.

---

## Advancing the Adverse Outcome Pathway Framework—An International Horizon Scanning Approach

Carlie A. LaLone,<sup>a,\*</sup> Gerald T. Ankley,<sup>b</sup> Scott E. Belanger,<sup>b</sup> Michelle R. Embry,<sup>c</sup> Geoff Hodges,<sup>d</sup> Dries Knapen,<sup>e</sup> Sharon Munn,<sup>f</sup> Edward J. Perkins,<sup>g</sup> Murray A. Rudd,<sup>g</sup> Daniel L. Villeneuve,<sup>a</sup> Maurice Whelan,<sup>f</sup> Catherine Willett,<sup>i</sup> Xiaowei Zhang,<sup>j</sup> and Markus Hecker<sup>k,\*</sup>

### **Sessions at Professional Meetings:**

- Session at the 2017 SETAC NA meeting in Minneapolis
- Session at the 2018 SOT meeting in San Antonio
- Session at the 2018 SETAC Europe meeting in Rome
- Session at the 2018 SETAC Asia Pacific meeting in Daegu

### **Publications:**

LaLone, C.A., Ankley, G.T., Belanger, S.E., Embry, M.R., Hodges, G., Knapen, D., Munn, S., Perkins, E.J., Rudd, M.A., Villeneuve, D.L. and Whelan, M., 2017. Advancing the adverse outcome pathway framework—An international horizon scanning approach. *Environmental toxicology and chemistry*, 36(6), pp.1411-1421.

Knapen, D., Angrish, M.M., Fortin, M.C., Katsiadaki, I., Leonard, M., Margiotta-Casaluci, L., Munn, S., O'Brien, J.M., Pollesch, N., Smith, L.C. and Zhang, X., 2018. Adverse outcome pathway networks I: development and applications. *Environmental toxicology and chemistry*, 37(6), pp.1723-1733.

Villeneuve, D.L., Angrish, M.M., Fortin, M.C., Katsiadaki, I., Leonard, M., Margiotta-Casaluci, L., Munn, S., O'Brien, J.M., Pollesch, N.L., Smith, L.C. and Zhang, X., 2018. Adverse outcome pathway networks II: network analytics. *Environmental toxicology and chemistry*, 37(6), pp.1734-1748.

Pollesch, N.L., Villeneuve, D.L. and O'Brien, J.M., 2019. Extracting and benchmarking emerging adverse outcome pathway knowledge. *Toxicological Sciences*, 168(2), pp.349-364.

Perkins, E.J., Ashauer, R., Burgoon, L., Conolly, R., Landesmann, B., Mackay, C., Murphy, C.A., Pollesch, N., Wheeler, J.R., Zupanec, A. and Scholz, S., 2019. Building and applying quantitative adverse outcome pathway models for chemical hazard and risk assessment. *Environmental toxicology and chemistry*, 38(9), pp.1850-1865.

Coady, K., Browne, P., Embry, M., Hill, T., Leinala, E., Steeger, T., Maślankiewicz, L. and Hutchinson, T., 2019. When are adverse outcome pathways and associated assays “fit for purpose” for regulatory decision-making and management of chemicals?. *Integrated environmental assessment and management*, 15(4), pp.633-647.

Carusi, A., Davies, M.R., De Grandis, G., Escher, B.I., Hodges, G., Leung, K.M., Whelan, M., Willett, C. and Ankley, G.T., 2018. Harvesting the promise of AOPs: An assessment and recommendations. *Science of the Total Environment*, 628, pp.1542-1556.

Hecker, M. and LaLone, C.A., 2019. Adverse outcome pathways: moving from a scientific concept to an internationally accepted framework. *Environmental toxicology and chemistry*, 38(6), pp.1152-1163.

### **Workshops:**

- Science with impact in an era of information overload (June 2021)

**Theme (Workgroup) 1: Adverse outcome pathway networks and their applications**

Name	Sector	Location
Dries Knapen (leader)	Academia	Belgium
Dan Villeneuve (leader)	Government	US
Sharon Munn	Government	EU
Xiaowei Zhang	Academia	China
Jason O'Brien	Government	Canada
Ioanna Katsiadaki	Government	UK
Luigi Margiotta-Casaluci	Academia	UK
Marc Leonard	Industry	France
Marie Fortin	Industry	US
Michelle Angrish	Postdoc	US
L. Cody Smith	Grad Student	US

**Theme (Workgroup) 2: Quantitative adverse outcome pathways and their applications**

Name	Sector	Location
Stefan Scholz (leader)	Academia	EU
Ed Perkins (leader)	Government	US
Cameron Mackay	Industry	UK
Cheryl Murphy	Academia	US
Anze Zupanic	Academia	Switzerland
Brigitte Landesmann	Government	EU
Rory Conolly	Government	US
James Wheeler	Industry	UK
Roman Ashauer	Academia	UK
Nathan Pollesch	Postdoc	US

**Theme (Workgroup) 3: Regulatory use of the adverse outcome pathway framework**

Name	Sector	Location
Katie Coady (leader)	Industry	US
Patience Browne (leader)	OECD	EU
Michelle Embry	Industry	US
Tom Steeger	Government	US
Lidka Wijkhuizen-Maslankiewicz	Government	EU
Eeva Leinala	OECD	EU
Tom Hutchinson	Academia	UK
Thomas Hill	Postdoc	US

**Theme (Workgroup) 4: Roadmap to expand awareness of, involvement in, and application of the AOP framework and AOP knowledgebase in the broader scientific and regulatory/environmental policy communities**

Name	Sector	Location
Annamaria Carusi (leader)	Academia	UK
Gary Ankley (leader)	Government	US
Maurice Whelan	Government	EU
Kate Willett	NGO	US
Geoff Hodges	Industry	UK
Kenny Leung	Academia	Hong Kong
Beate Escher	Academia	EU
Mark Davies	Industry	UK
Giovanni De Grandis	Postdoc	EU